Evidence map›Paper›PMID 42395694›Full record

ArticleRSC advances2026

High-sensitivity photoelectric sensing of apatinib for recurrent hepatocellular carcinoma in TACE.

Senlin Yang, Zhihua Deng

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Senlin YangDepartment of Gastroenterology, The Second Hospital of Shanxi Medical University Taiyuan Shanxi 030001 China dzh_yk@hotmail.com.
Zhihua DengDepartment of Gastroenterology, The Second Hospital of Shanxi Medical University Taiyuan Shanxi 030001 China dzh_yk@hotmail.com.ORCID https://orcid.org/0009-0002-6150-9858

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with transcatheter arterial chemoembolization (TACE) being a widely used treatment for intermediate-stage patients. However, TACE is often associated with high recurrence rates, necessitating reliable methods for early detection and prediction of tumor recurrence. Current diagnostic tools rely heavily on imaging techniques and biomarkers, which often lack sensitivity and specificity, particularly in the early stages of disease progression. To address these challenges, we developed an innovative integrated platform combining a high-sensitivity photoelectric sensor based on Bi/h-Bi

Identifiers

PMID42395694
PMCPMC13325549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.